The US Food and Drug Administration on Wednesday approved Gilead Sciences’ twice-yearly injection to prevent HIV — a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus. An earlier long-acting HIV prevention shot — cabotegravir, which is injected every two months and was approved by the FDA in 2021 — costs tens of thousands of dollars per year and has yet to make a major global impact.